Medical resource use and costs among pain patients with potential opioid-tolerability issues

Authors

  • Noam Y. Kirson, PhD
  • Amie Shei, PhD
  • Howard G. Birnbaum, PhD
  • Rami Ben-Joseph, PhD
  • Edward Michna, MD

DOI:

https://doi.org/10.5055/jom.2014.0220

Keywords:

opioids, tolerability, side effects

Abstract

Objective: To estimate excess medical resource use and costs associated with prescription opioid (RxO) tolerability issues.

Design: This was an observational, retrospective analysis of deidentified administrative claims data.

Setting: The study included commercially insured patients treated in different healthcare settings captured in the Truven MarketScan claims database.

Patients: Patients aged 18-64 years initiating treatment with an RxO (index) and continuously treated with pain relievers over a 6-month period were selected. “Switchers” were patients who discontinued their index RxO and switched to non-RxO pain relievers <30 days post-index, and whose last pain reliever in the 6-month follow-up period was not an RxO. Such switching was considered a proxy for RxO-tolerability issues. “Continuous RxO users” were patients who remained on the index RxO for the follow-up period. Switchers and continuous RxO users were matched 1:1 on propensity score, baseline medical costs, index RxO days supply, and short-/long-acting index RxO.

Main Outcome Measures: Six-month follow-up medical resource use and costs were compared between matched switchers and continuous RxO users.

Results: A total of 10,704 pairs of switchers and continuous RxO users were matched. In the 6-month follow-up period, switchers had more outpatient (7.5 vs 6.8; p < 0.001) and inpatient (0.05 vs 0.04; p = 0.002) visits and longer inpatient stays (0.26 days vs 0.19; p = 0.006) compared to continuous RxO users. Switchers also had higher total medical costs ($4,522 vs $3,657; p < 0.001).

Conclusions: Switchers incur greater medical resource use and costs than similar patients continuously treated with their index RxO.

 

Author Biographies

Noam Y. Kirson, PhD

Manager, Analysis Group, Inc., Boston, Massachusetts

Amie Shei, PhD

Associate, Analysis Group, Inc., Boston, Massachusetts

Howard G. Birnbaum, PhD

Principal, Analysis Group, Inc., Boston, Massachusetts

Rami Ben-Joseph, PhD

Head of Health Outcomes and PharmacoEconomics, Purdue Pharma L.P., Boston, Massachusetts

Edward Michna, MD

Anesthesiologist, Brigham and Women's Hospital, Boston, Massachusetts

References

IOM (Institute of Medicine): Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press, 2011.

Stewart WF, Ricci JA, Chee E, et al.: Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003; 290(18): 2443-2454. DOI: https://doi.org/10.1001/jama.290.18.2443

U.S. Food and Drug Administration: Guidance for industry. Abuse-deterrent opioids—Evaluation and labeling. Draft guidance, January 2013. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed February 2013.

Benyamin R, Trescot AM, Datta S, et al.: Opioid complications and side effects. Pain Physician. 2008; 11(2 Suppl): S105-S120. DOI: https://doi.org/10.36076/ppj.2008/11/S105

Iyer S, Davis KL, Candrilli S: Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010; 19(3): 44-51. DOI: https://doi.org/10.1080/15360280903098440

Ivanova JI, Birnbaum HG, Yushkina Y, et al.: The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain. J Opioid Manag. 2013; 9(4): 239-254. DOI: https://doi.org/10.5055/jom.2013.0165

Gregorian RS Jr, Gasik A, Kwong WJ, et al.: Importance of side effects in opioid treatment: A trade-off analysis with patients and physicians. J Pain. 2010; 11(11): 1095-1108. DOI: https://doi.org/10.1016/j.jpain.2010.02.007

Boswell K, Kwong WJ, Kavanagh S: Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: A systematic literature review. J Opioid Manag. 2010; 6(4): 269-289. DOI: https://doi.org/10.5055/jom.2010.0025

Truven Health Analytics: MarketScan Commercial Claims and Encounters Research Databases. Ann Arbor, MI: Truven Health Analytics, 2008: 12.

Hess B, Bernardi M, Klotz HP: Attitude of Swiss physicians towards opioid-induced constipation: A national survey. Eur J Intern Med. 2011; 22(5): 527-531. DOI: https://doi.org/10.1016/j.ejim.2011.02.014

Published

09/01/2014

How to Cite

Kirson, PhD, N. Y., A. Shei, PhD, H. G. Birnbaum, PhD, R. Ben-Joseph, PhD, and E. Michna, MD. “Medical Resource Use and Costs Among Pain Patients With Potential Opioid-Tolerability Issues”. Journal of Opioid Management, vol. 10, no. 5, Sept. 2014, pp. 305-10, doi:10.5055/jom.2014.0220.

Similar Articles

You may also start an advanced similarity search for this article.